GlassScriptPhysician profile
Marvin P Davis
NPI 1245212638
$3,225.68
in general payments reported to CMS, 2019-2025
29 companies · $521 in 2025
The $521 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $433 · 2021: $243 · 2022: $322 · 2023: $793 · 2024: $575 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.47 |
| Education | $244.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $738.76 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $370.07 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Organon LLC | $274.37 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $246.54 | 2022-2025 | Novasure, Myosure Tissue Removal Device, Omni Hysteroscope |
| Merz North America, INC. | $233.20 | 2020 | |
| Merck Sharp & Dohme LLC | $226.58 | 2019-2025 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $214.88 | 2019-2025 | |
| Sage Therapeutics, LLC | $85.29 | 2021-2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $72.44 | 2022 | |
| Therapeuticsmd, INC. | $72.38 | 2019-2020 | |
| Amgen INC. | $57.21 | 2019-2025 | Evenity, Prolia, Prolia |
| Channel Medsystems, INC. | $55.13 | 2023 | |
| Aspira Women'S Health INC | $55.11 | 2022-2025 | Ova1 |
| Agile Therapeutics, INC. | $52.05 | 2021-2022 | |
| Shield Therapeutics INC | $51.19 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $50.97 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Myovant Sciences INC. | $48.45 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $44.60 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $44.13 | 2023-2025 | |
| Evofem Biosciences, INC. | $43.92 | 2020-2021 | |
| Scynexis, INC. | $42.51 | 2022 | |
| Coopersurgical, INC. | $34.94 | 2019-2024 | Paragard T 380a |
| Galderma Laboratories, L.P. | $30.56 | 2021-2025 | |
| Allergan, INC. | $23.83 | 2019 | |
| Exeltis, USA INC. | $18.21 | 2024 | Slynd |
| Lupin INC. | $15.12 | 2019 | |
| Mckesson Patient Care Solutions INC. | $11.90 | 2019 | |
| Duchesnay USA Incorporated | $11.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.